Jane Street Group LLC Has $128,000 Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Jane Street Group LLC reduced its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 74.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 23,731 shares of the biotechnology company’s stock after selling 69,415 shares during the period. Jane Street Group LLC’s holdings in Aldeyra Therapeutics were worth $128,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. US Bancorp DE acquired a new stake in Aldeyra Therapeutics during the third quarter worth approximately $30,000. Paloma Partners Management Co bought a new position in Aldeyra Therapeutics in the third quarter valued at approximately $62,000. The Manufacturers Life Insurance Company increased its stake in Aldeyra Therapeutics by 14.4% in the second quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 2,729 shares during the last quarter. King Wealth Management Group boosted its position in Aldeyra Therapeutics by 24.5% in the third quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 2,700 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in Aldeyra Therapeutics by 253.3% in the third quarter. BNP Paribas Financial Markets now owns 14,229 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 10,201 shares in the last quarter. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Aldeyra Therapeutics Trading Down 3.4 %

Shares of Aldeyra Therapeutics stock opened at $4.77 on Tuesday. Aldeyra Therapeutics, Inc has a fifty-two week low of $2.71 and a fifty-two week high of $6.55. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. The company’s 50 day moving average price is $4.98 and its two-hundred day moving average price is $4.94.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, hitting analysts’ consensus estimates of ($0.25). On average, equities analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.